



ASX ANNOUNCEMENT

2 January 2024

### ASX CONDITIONAL APPROVAL TO LIFT SUSPENSION

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) is pleased to announce that following the launch of its \$4 million placement (with tranche 2 subject to shareholder approval) (**Placement**) and pro rata entitlement offer of up to \$4 million (**Entitlement Offer**), in each case with attaching quoted options, the Company has been able to progress discussions with ASX as to lifting the suspension in trading of the Company's shares which has been in place since 28 September 2023.

Based on additional financial information provided by the Company (including a 30 November 2023 consolidated statement of financial position), ASX has now advised that it is minded to reinstate trading in the Company's shares on the following conditions:

1. Confirmation that \$8 million has been raised pursuant to the Placement and Entitlement Offer, and that these shares and options have been issued.
2. Confirmation in a form acceptable to ASX that CDX has received cleared funds for the proceeds from the Placement and Entitlement Offer for the issue price of every security allotted and issued to every successful applicant for securities.
3. Receipt of an updated pro-forma balance sheet as at the time of reinstatement based upon the 31 December 2023 statement of financial position, demonstrating that CDX's financial position has not deteriorated materially from the 30 November 2023 pro-forma position referred to above.
4. CDX demonstrating compliance with Listing Rules 12.1 and 12.2, to the satisfaction of ASX including:
  - (a) Providing a 'working capital statement' similar to that required by Listing Rule 1.3.3(b) to the effect that following completion of the Placement and Entitlement Offer, CDX will have sufficient working capital at the time of reinstatement to carry its stated objectives; and
  - (b) Satisfying the 'working capital test' of at least \$1.5 million pursuant to Listing Rule 1.3.3(c).
5. Lodgement of any outstanding periodic reports.
6. Lodgement of all Appendices 3B and 2A with ASX for proposed and actual issues of new securities.
7. Lodgement of Directors' Interest Notices, being either Appendices 3X, 3Y, or 3Z, as required.

To assist with satisfaction of condition 1 above, the Company is progressing several initiatives to ensure that the full \$4 million amount of the Entitlement Offer will be obtained including seeking commitments from existing shareholders to take up their entitlement, seeking commitments from existing and new investors for placement of defined amounts of any shortfall, and potentially partially underwriting any remaining shortfall.

The Company does not believe that there will be any deterioration in its financial position as referred to in condition 3 above.

The Company notes that reinstatement to trading is a discretionary step by ASX, and while the clarity provided by ASX in the form of the above conditions is welcomed ASX does reserve the right to impose further conditions should circumstances change or new matters come to light.

**Approved by the Board of Directors and Released by the Company Secretary**

**- ENDS -**

For more information, please contact:

**Investor Relations**

Rod Hinchcliffe  
rod.hinchcliffe@mcpartners.com.au

**Media Relations**

Melissa Hamilton  
melissa.hamilton@mcpartners.com.au

**Investor Relations – USA**

Matt Selinger  
Managing Director, Integrous Communications  
mselinger@integcom.com

**About CardieX**

CardieX is a medical technology company that develops and markets non-invasive patient monitoring technologies for assessing vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CardieX is listed on the Australian Stock Exchange ("CDX").